(1-甲基-1H-吡咯-2-yl)甲基胺 | 69807-81-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1-甲基-1H-吡咯-2-yl)甲基胺
• 中文别名: (1-甲基-1H-吡咯-2-基)甲胺盐酸盐；[(1-甲基-1H-吡咯-2-基)甲基]胺盐酸盐
• 英文名称: 2-aminomethyl-1-methyl-1H-pyrrole
• 英文别名: (1-methyl-1H-pyrrol-2-yl)methanamine；(1-methyl-1H-pyrrol-2-ylmethyl)amine；(1-methylpyrrol-2-yl)methanamine
• CAS: 69807-81-4
• 化学式: C₆H₁₀N₂
• mdl: MFCD02677708
• 分子量: 110.159
• InChiKey: GGCBARJYVAPZJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  58 °C
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险品运输编号：
  UN 2735
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	(1-Methyl-1H-pyrrol-2-yl)methylamine 97% Material Safety Data Sheet
Synonym:
CAS:	69807-81-4

Section 1 - Chemical Product MSDS Name:(1-Methyl-1H-pyrrol-2-yl)methylamine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
69807-81-4	(1-Methyl-1H-pyrrol-2-yl)methylamine	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.) Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 69807-81-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 53 - 57 deg C @0.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H10N2
Molecular Weight: 110

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides, halogens, halogenated agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 69807-81-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(1-Methyl-1H-pyrrol-2-yl)methylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 69807-81-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 69807-81-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 69807-81-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1-甲基-1H-吡咯-2-yl)甲基胺 在 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 19.0h， 生成 N-{5-[4-(2-Methoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-acetamide;succinate
  参考文献：
  名称：

  哌嗪基烷基杂环作为潜在的抗精神病药。

  摘要：

  我们最近报道了一系列吡咯曼尼希碱在抑制大鼠条件性回避反应（CAR）方面具有口服活性。这些化合物对D2和5-HT1A受体均具有亲和力，并且有些是非致死肽的。这样的特征表明它们可能是潜在的抗精神病药，它们缺乏引起人锥体外系副作用和迟发性运动障碍的倾向。这些化合物之一，1-[[1-甲基-5-[[4- [2-（1-甲基乙氧基）苯基] -1-哌嗪基]甲基] -1H-吡咯-2-基]甲基] -2-选择哌啶酮（RWJ 25730，1）进行进一步开发，但发现在稀酸中不稳定。为了提高稳定性，我们用乙烯取代了哌嗪环上的吡咯亚甲基键，并使用乙烯和二羰基作为内酰胺和吡咯环之间的连接基，在吡咯环上放置吸电子基团，并用无环酰胺取代内酰胺。此外，我们用其他杂环取代了吡咯片段，包括噻吩，呋喃，异恶唑，异恶唑啉和吡啶。通常，用噻吩，呋喃，异恶唑啉或吡啶取代N-甲基吡咯片段可得到在CAR中与1等价的化合物，它们在稀酸中更稳定。

  DOI：

  10.1021/jm00021a009
• 作为产物：
  描述：

  1-methyl-1H-pyrrole-2-carbaldehyde oxime 在 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、405.33 kPa 条件下， 生成 (1-甲基-1H-吡咯-2-yl)甲基胺
  参考文献：
  名称：

  新型杂芳基甲基氨基甲酸二硫代磺酸盐作为有效的抗癌药的发现：合成，构效关系分析和生物学评价

  摘要：

  设计，合成和评估了一系列基于铅化合物10结构的新类似物，它们针对四种选定的人类癌细胞系（HL-60，Bel-7402，SK-BR-3和MDA）的体外抗癌活性-MB-468）。与铅化合物10相比，几种合成的化合物表现出改善的抗癌活性。其中，1,3,4-恶二唑类似物17o对Bel-7402，SK-BR-3和MDA-MB-468细胞表现出最高的生物活性，IC 50值分别为1.23、0.58和4.29μM。值得注意的是17o具有对癌细胞的有效抗增殖活性，对非恶性细胞的细胞毒性相对较小。进一步的机理研究表明，它通过破坏有丝分裂进程中的纺锤体组装诱导细胞凋亡和细胞周期停滞，表明这些合成的二硫代氨基甲酸酯代表了一系列针对有丝分裂的新型抗癌化合物。

  DOI：

  10.1016/j.ejmech.2016.02.015

文献信息

• Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake:  Comparison with Effects on Fatty Acid Amidohydrolase
  作者：María L. López-Rodríguez、Alma Viso、Silvia Ortega-Gutiérrez、Christopher J. Fowler、Gunnar Tiger、Eva de Lago、Javier Fernández-Ruiz、José A. Ramos

  DOI：10.1021/jm0210818

  日期：2003.4.1

  A new series of arachidonic acid derivatives were synthesized and evaluated as inhibitors of the endocannabinoid uptake. Most of them are able to inhibit anandamide uptake with IC(50) values in the low micromolar range (IC(50) = 0.8-24 microM). In general, the compounds had only weak effects upon CB(1), CB(2), and VR(1) receptors (K(i) > 1000-10000 nM). In addition, there was no obvious relationship

  合成了一系列新的花生四烯酸衍生物，并将其评估为内源性大麻素吸收的抑制剂。它们中的大多数能够以较低的微摩尔范围（IC（50）= 0.8-24 microM）的IC（50）值抑制anandamide的吸收。通常，这些化合物对CB（1），CB（2）和VR（1）受体的作用很小（K（i）> 1000-10000 nM）。此外，化合物通过脂肪酸酰胺水解酶（FAAH； IC（50）= 30-113 microM）影响anandamide摄取和抑制anandamide代谢的能力之间没有明显的关系。这表明该化合物对FAAH抑制没有发挥第二作用。希望这些化合物，尤其是本系列中最有效的化合物（化合物5，UCM707，其对Anandamide的吸收和FAAH的IC（50）值分别为0.8和30 microM），
• Modification of Estrone at the 6, 16, and 17 Positions:  Novel Potent Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
  作者：Gillian M. Allan、Harshani R. Lawrence、Josephine Cornet、Christian Bubert、Delphine S. Fischer、Nigel Vicker、Andrew Smith、Helena J. Tutill、Atul Purohit、Joanna M. Day、Mary F. Mahon、Michael J. Reed、Barry V. L. Potter

  DOI：10.1021/jm050830t

  日期：2006.2.1

  androgens and estrogens at the 17 position. The 17beta-HSD type 1 enzyme (17beta-HSD1) catalyzes the reduction of estrone to estradiol and is expressed in malignant breast cells. Inhibitors of this enzyme thus have potential as treatments for hormone dependent breast cancer. Here we report the syntheses and biological evaluation of novel inhibitors based on the estrone or estradiol template. These have

  17beta-羟基类固醇脱氢酶（17beta-HSDs）催化在17位的雄激素和雌激素的氧化形式和还原形式之间的相互转化。17beta-HSD 1型酶（17beta-HSD1）催化雌酮还原为雌二醇，并在恶性乳腺癌细胞中表达。因此，这种酶的抑制剂具有治疗激素依赖性乳腺癌的潜力。在这里，我们报告基于雌酮或雌二醇模板的新型抑制剂的合成和生物学评估。已经通过在6、16或17位的修饰或它们的组合来研究这些，以便通过探测酶活性位点的不同区域来获得关于结构-活性关系的信息。活动数据已被纳入具有预测能力的QSAR中，并且已经确定了化合物15和16c的X射线晶体结构。化合物15对17beta-HSD1的IC50为320 nM，并且对17beta-HSD1的选择性超过17beta-HSD2。还报告了三个酰胺库，这些化合物导致了抑制剂19e和20a的鉴定，它们的IC50值分别为510和380 nM，在20 h时，IC50值为37
• Design, Synthesis and Biological Evaluation of Novel Arachidonic Acid Derivatives as Highly Potent and Selective Endocannabinoid Transporter Inhibitors
  作者：María L. López-Rodríguez、Alma Viso、Silvia Ortega-Gutiérrez、Isabel Lastres-Becker、Sara González、Javier Fernández-Ruiz、José A. Ramos

  DOI：10.1021/jm015545y

  日期：2001.12.1

  In the present work, we have designed and synthesized a series of arachidonic acid derivatives of general structure I which have been characterized as highly potent and selective inhibitors of anandamide transporter (IC(50) = 24-0.8 microM, K(i) > 1000-5000 nM for CB(1) and CB(2) cannabinoid receptors and vanilloid VR(1) receptor). Among them, N-(3-furylmethyl)eicosa-5,8,11,14-tetraenamide deserves

  在目前的工作中，我们已经设计并合成了一系列具有通用结构I的花生四烯酸衍生物，这些衍生物被表征为高效和选择性的Anandamide转运蛋白抑制剂（IC（50）= 24-0.8 microM，K（i）> 1000 -5000 nM用于CB（1）和CB（2）大麻素受体和香草类VR（1）受体）。其中，N-（3-呋喃甲基）二十碳五，8、11、14-四烯酰胺是迄今为止描述的最有效的内源性大麻素转运蛋白抑制剂（IC（50）= 0.8 microM），值得特别关注。
• Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors
  作者：Marı́a L. López-Rodrı́guez、Alma Viso、Silvia Ortega-Gutiérrez、Christopher J. Fowler、Gunnar Tiger、Eva de Lago、Javier Fernández-Ruiz、José A. Ramos

  DOI：10.1016/s0223-5234(03)00045-x

  日期：2003.4

  describe the synthesis and the in vitro evaluation of a series of arachidonic acid derivatives of general structure I as endocannabinoid transporter inhibitors. In addition, we report the first in vivo studies of the most potent derivative (4, UCM707) within this series. The majority of compounds studied are highly potent (IC(50)=24-0.8 micro M) and selective endocannabinoid uptake inhibitors with very

  在本工作中，我们描述了一系列具有通用结构I作为内源性大麻素转运蛋白抑制剂的花生四烯酸衍生物的合成和体外评估。此外，我们报告了该系列中最有效的衍生物（4，UCM707）的首次体内研究。所研究的大多数化合物都是高效的（IC（50）= 24-0.8 micro M）和选择性的内源性大麻素吸收抑制剂，对脂肪酸酰胺水解酶（IC（50）= 30-113 micro M）或对于大麻素受体亚型1（CB（1）），大麻素受体亚型2（CB（2））和香草类受体亚型1（VR（1））（K（i）= 1000-10000 nM）。其中（5Z，8Z，11Z，14Z）-N-（fur-3-ylmethyl）icosa-5,8,11,14-tetraenamide（UCM707）表现为迄今为止描述的最有效的内源性大麻素转运蛋白抑制剂（IC（ 50）= 0。8 micro M）并显示出对anandamide转运蛋白的增强效力，对C
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。